• Please log in or register to access this feature.
You have full text access to this OnlineOpen article

Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial

  1. A.J. Duffield-Lillico1,
  2. B.L. Dalkin2,
  3. M.E. Reid3,
  4. B.W. Turnbull4,
  5. E.H. Slate5,
  6. E.T. Jacobs1,
  7. J.R. Marshall3,*,
  8. L.C. Clark1,
  9. for the Nutritional Prevention of Cancer Study Group1

Article first published online: 16 APR 2003

DOI: 10.1046/j.1464-410X.2003.04167.x

Issue

BJU International

BJU International

Volume 91, Issue 7, pages 608–612, May 2003

Additional Information

How to Cite

Duffield-Lillico, A.J., Dalkin, B.L., Reid, M.E., Turnbull, B.W., Slate, E.H., Jacobs, E.T., Marshall, J.R., Clark, L.C. and for the Nutritional Prevention of Cancer Study Group (2003), Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International, 91: 608–612. doi: 10.1046/j.1464-410X.2003.04167.x

Author Information

  1. 1

    Arizona Cancer Center, and

  2. 2

    Urology Section, Department of Surgery, Arizona Cancer Center, College of Medicine, University of Arizona, Tucson, AZ,

  3. 3

    Cancer Prevention & Population Sciences, Roswell Park Cancer Institute, Buffalo, NY,

  4. 4

    School of Operations Research and Industrial Engineering, Cornell University, Ithaca, NY and

  5. 5

    Department of Biometry and Epidemiology, Medical University of South Carolina, Charleston, SC, USA

* J.R. Marshall, PhD, Senior Vice President for Cancer Prevention & Population Sciences, Roswell Park Cancer Institute, Carlton House Building, Room 304, Elm & Carlton Streets, Buffalo, NY 14263, USA. e-mail: james.marshall@roswellpark.org

Publication History

  1. Issue published online: 16 APR 2003
  2. Article first published online: 16 APR 2003
  3. Accepted for publication 30 January 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (77K)

REFERENCES

  • 1
    Clark LC, Combs GF Jr, Turnbull BW et al. for the Nutritional Prevention of Cancer Study Group. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. JAMA 1996; 276: 1957 – 63
  • 2
    Clark LC, Dalkin B, Krongrad A et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998; 81: 730 – 4
  • 3
    Hoedemaeker RF, Vis AN, Van Der Kwast TH. Staging prostate cancer. Microsc Res Tech 2000; 51: 423 – 9
    Direct Link:
  • 4
    Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283 – 90
  • 5
    Schroder FH, Van Der Maas P, Beemsterboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998; 90: 1817 – 23
  • 6
    Maattanen L, Auvinen A, Stenman UH et al. European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer 1999; 79: 1210 – 4
  • 7
    Brooks JD, Metter EJ, Chan DW et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001; 166: 2034 – 8
  • 8
    Yoshizawa K, Willett WC, Morris SJ et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998; 90: 1219 – 24
  • 9
    Nomura AM, Lee J, Stemmermann GN, Combs GF Jr. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 883 – 7
  • 10
    West DW, Slattery ML, Robison LM, French TK, Mahoney AW. Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. Cancer Causes Control 1991; 2: 85 – 94
  • 11
    Willett WC, Polk BF, Morris JS et al. Prediagnostic serum selenium and risk of cancer. Lancet 1983; 2: 130 – 4
  • 12
    Coates RJ, Weiss NS, Daling JR, Morris JS, Labbe RF. Serum levels of selenium and retinol and the subsequent risk of cancer. Am J Epidemiol 1988; 128: 515 – 23
  • 13
    Helzlsouer KJ, Huang HY, Alberg AJ et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000; 92: 2018 – 23
  • 14
    Webber MM, Perez-Ripoll EA, James GT. Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro. Biochem Biophys Res Commun 1985; 130: 603 – 9
  • 15
    Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 2000; 9: 1171 – 82
  • 16
    Jiang C, Wang Z, Ganther H, Lu J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001; 61: 3062 – 70
  • 17
    Kumaraswamy E, Malykh A, Korotkov KV et al. Structure-Expression Relationships of the 15-kDa Selenoprotein Gene. Possible role of the protein in cancer etiology. J Biol Chem 2000; 275: 35540 – 7
  • 18
    Moul JW. Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials. Urology 2001; 57: 174 – 7
  • 19
    Cook NR, Stampfer MJ, Ma J et al. Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer 1999; 86: 1783 – 92
    Direct Link:
  • 20
    Colditz GA. Selenium and cancer prevention. Promising results indicate further trials required. JAMA 1996; 276: 1984 – 5
  • 21
    Clark LC, Marshall JR. Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer. Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia. Urology 2001; 57: 185 – 7
  • 22
    Klein EA, Thompson IM, Lippman SM et al. SELECT. The next prostate cancer prevention trial. J Urol 2001; 166: 1311 – 5
View Full Article (HTML) Get PDF (77K)